Lenalidomid Abz

Lenalidomide, the active ingredient in Lenalidomid Abz, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomid Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomid Abz is an immunomodulatory agent used in hematologic malignancies and bone‑marrow failure syndromes.

Multiple myeloma: improves disease control and prolongs progression‑free survival. Myelodysplastic syndromes: reduces transfusion dependence and may improve blood counts. Mantle cell lymphoma (in selected settings): contributes to response rates when combined with other agents.

Lenalidomid Abz may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Thrombocytopenia: low platelet count leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often occurring after dosing. - Diarrhea: loose stools that may require hydration. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophil levels requiring medical intervention. - Severe thrombocytopenia: dangerously low platelets causing hemorrhage. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Hepatic failure: significant liver enzyme elevation or dysfunction.

Before initiating Lenalidomid Abz, clinicians should consider several safety measures.

Pregnancy contraindication: product is classified Category X; avoid use in pregnant women. Blood count monitoring: perform regular CBC to detect neutropenia or thrombocytopenia. Thrombotic risk assessment: evaluate for prior clotting events and consider prophylaxis. Renal function evaluation: adjust use in patients with severe renal impairment. Hypersensitivity screening: discontinue if severe allergic reaction occurs. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Lenalidomid Abz can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Live vaccines: potential for uncontrolled infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - NSAIDs: additive effect on platelet inhibition. - Digoxin: possible alteration of serum concentrations. - Hormonal contraceptives: reduced efficacy, consider alternative methods.